William T. Creasman

William T. Creasman

Obstetrics and Gynecology

86 Jonathan Lucas St
86 Jonathan Lucas St
Charleston, SC 29425

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol.

Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol.

Journal: Gynecologic oncology

Published: August 04, 2025

Letter to the Editor: 2023 FIGO staging system for endometrial cancer.

Letter to the Editor: 2023 FIGO staging system for endometrial cancer.

Journal: International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

Published: July 21, 2023

A Case for the Conservative Management of Stage IA Cervical Cancer.

A Case for the Conservative Management of Stage IA Cervical Cancer.

Journal: Cancers

Published: July 11, 2023

Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 women.

Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 women.

Journal: Gynecologic oncology

Published: May 16, 2023

The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women.

The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women.

Journal: Gynecologic oncology

Published: December 02, 2020

Surgical training in gynecologic oncology: Past, present, future.

Surgical training in gynecologic oncology: Past, present, future.

Journal: Gynecologic oncology

Published: March 18, 2020

Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study.

Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study.

Journal: American journal of obstetrics and gynecology

Published: June 06, 2018

An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.

An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.

Journal: Gynecologic oncology

Published: August 23, 2017

Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study.

Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study.

Journal: International journal of cancer

Published: June 27, 2017

Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study.

Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study.

Journal: Gynecologic oncology

Published: April 06, 2017

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).

Journal: Lancet (London, England)

Published: April 02, 2017

Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol.

Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol.

Journal: Gynecologic oncology

Published: February 14, 2017

Showing 1-12 of 35

Last Updated: 09/26/2026